Fidelity Investments’s TScan Therapeutics TCRX Stock Holding History

Fidelity Investments’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37K	Buy	1,400 +100	+8%	+$107	﹤0.01%	5199
2026 Q1	$1.31K	Buy	1,300 +800	+160%	+$855	﹤0.01%	5082
2025 Q4	$500	Sell	500 -9,493	-95%	-$13.7K	﹤0.01%	5155
2025 Q3	$18.2K	Sell	9,993 -885	-8%	-$1.57K	﹤0.01%	4390
2025 Q2	$15.8K	Sell	10,878 -11,000	-50%	-$15.9K	﹤0.01%	4372
2025 Q1	$30.2K	Buy	21,878 +20,428	+1,409%	+$44.2K	﹤0.01%	4074
2024 Q4	$4.41K	Buy	1,450 +1,025	+241%	+$4.65K	﹤0.01%	4689
2024 Q3	$2.12K	Buy	+425	New	+$2.56K	﹤0.01%	4802

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Fidelity Investments's TCRX Position: Q2 2026 in Review

Fidelity Investments increased its TScan Therapeutics (TCRX) stake by 7.7% in Q2 2026, buying an estimated $107 and bringing the position to 1,400 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #5199.

Fidelity Investments first reported a position in TCRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $30.2K in Q1 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Fidelity Investments held 1,400 shares of TScan Therapeutics worth $1.37K as of Q2 2026.
Fidelity Investments bought 100 TScan Therapeutics shares in Q2 2026, an estimated $107.
TScan Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5199 holding.
Fidelity Investments first reported a position in TScan Therapeutics in Q3 2024 and has held it in 8 quarters since.
Fidelity Investments's TScan Therapeutics position peaked at $30.2K in Q1 2025.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.